Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.

Compte M, Harwood SL, Muñoz IG, Navarro R, Zonca M, Perez-Chacon G, Erce-Llamazares A, Merino N, Tapia-Galisteo A, Cuesta AM, Mikkelsen K, Caleiras E, Nuñez-Prado N, Aznar MA, Lykkemark S, Martínez-Torrecuadrada J, Melero I, Blanco FJ, Bernardino de la Serna J, Zapata JM, Sanz L, Alvarez-Vallina L.

Nat Commun. 2018 Nov 15;9(1):4809. doi: 10.1038/s41467-018-07195-w.

2.

Cytokines in clinical cancer immunotherapy.

Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I.

Br J Cancer. 2019 Jan;120(1):6-15. doi: 10.1038/s41416-018-0328-y. Epub 2018 Nov 9. Review.

PMID:
30413827
3.

For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity.

Marquez-Rodas I, Aznar MA, Calles A, Melero I.

Clin Cancer Res. 2019 Feb 15;25(4):1127-1129. doi: 10.1158/1078-0432.CCR-18-2690. Epub 2018 Sep 27.

PMID:
30262506
4.

International Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, Spain.

Berraondo P, Aznar MA, Perez-Ruiz E, Rodriguez-Ruiz ME, Castañon E, Perez-Gracia JL, Melero I.

Cancer Immunol Immunother. 2018 Nov;67(11):1809-1813. doi: 10.1007/s00262-018-2240-y. Epub 2018 Sep 4. No abstract available.

PMID:
30182281
5.

Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.

Teijeira A, Labiano S, Garasa S, Etxeberria I, Santamaría E, Rouzaut A, Enamorado M, Azpilikueta A, Inoges S, Bolaños E, Aznar MA, Sánchez-Paulete AR, Sancho D, Melero I.

Cancer Immunol Res. 2018 Jul;6(7):798-811. doi: 10.1158/2326-6066.CIR-17-0767. Epub 2018 Apr 20.

PMID:
29678874
6.

Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).

Azpilikueta A, Bolaños E, Lang V, Labiano S, Aznar MA, Etxeberria I, Teijeira A, Rodriguez-Ruiz ME, Perez-Gracia JL, Jure-Kunkel M, Zapata JM, Rodriguez MS, Melero I.

Oncoimmunology. 2017 Sep 21;7(1):e1368605. doi: 10.1080/2162402X.2017.1368605. eCollection 2017.

7.

CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes.

Aznar MA, Labiano S, Diaz-Lagares A, Molina C, Garasa S, Azpilikueta A, Etxeberria I, Sanchez-Paulete AR, Korman AJ, Esteller M, Sandoval J, Melero I.

Cancer Immunol Res. 2018 Jan;6(1):69-78. doi: 10.1158/2326-6066.CIR-17-0159. Epub 2017 Nov 13.

8.

CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes.

Labiano S, Meléndez-Rodríguez F, Palazón A, Teijeira Á, Garasa S, Etxeberria I, Aznar MÁ, Sánchez-Paulete AR, Azpilikueta A, Bolaños E, Molina C, de la Fuente H, Maiso P, Sánchez-Madrid F, de Landázuri MO, Aragonés J, Melero I.

Oncoimmunology. 2017 Jan 19;6(4):e1283468. doi: 10.1080/2162402X.2017.1283468. eCollection 2017.

9.

Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally.

Aznar MA, Tinari N, Rullán AJ, Sánchez-Paulete AR, Rodriguez-Ruiz ME, Melero I.

J Immunol. 2017 Jan 1;198(1):31-39. Review.

10.

Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.

Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S, Sanmamed MF, Azpilikueta A, Bolaños E, Sanchez-Paulete AR, Aznar MA, Rouzaut A, Schalper KA, Jure-Kunkel M, Melero I.

Cancer Res. 2016 Oct 15;76(20):5994-6005. Epub 2016 Aug 22.

11.

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.

Labiano S, Palazón A, Bolaños E, Azpilikueta A, Sánchez-Paulete AR, Morales-Kastresana A, Quetglas JI, Perez-Gracia JL, Gúrpide A, Rodriguez-Ruiz M, Aznar MA, Jure-Kunkel M, Berraondo P, Melero I.

Oncoimmunology. 2015 Jun 24;5(1):e1062967. eCollection 2016.

12.

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.

Azpilikueta A, Agorreta J, Labiano S, Pérez-Gracia JL, Sánchez-Paulete AR, Aznar MA, Ajona D, Gil-Bazo I, Larrayoz M, Teijeira A, Rodriguez-Ruiz ME, Pio R, Montuenga LM, Melero I.

J Thorac Oncol. 2016 Apr;11(4):524-36. doi: 10.1016/j.jtho.2016.01.013. Epub 2016 Feb 1.

13.

Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.

Sanchez-Paulete AR, Labiano S, Rodriguez-Ruiz ME, Azpilikueta A, Etxeberria I, Bolaños E, Lang V, Rodriguez M, Aznar MA, Jure-Kunkel M, Melero I.

Eur J Immunol. 2016 Mar;46(3):513-22. doi: 10.1002/eji.201445388. Epub 2016 Feb 9. Review.

14.

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.

Sánchez-Paulete AR, Cueto FJ, Martínez-López M, Labiano S, Morales-Kastresana A, Rodríguez-Ruiz ME, Jure-Kunkel M, Azpilikueta A, Aznar MA, Quetglas JI, Sancho D, Melero I.

Cancer Discov. 2016 Jan;6(1):71-9. doi: 10.1158/2159-8290.CD-15-0510. Epub 2015 Oct 22.

15.

Double Laser for Depth Measurement of Thin Films of Ice.

Beltrán MD, Molina RL, Aznar MÁ, Moltó CS, Verdú CM.

Sensors (Basel). 2015 Sep 29;15(10):25123-38. doi: 10.3390/s151025123.

16.

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL, Haanen J.

Nat Rev Cancer. 2015 Aug;15(8):457-72. doi: 10.1038/nrc3973. Review.

PMID:
26205340
17.

Upper limb rehabilitation after spinal cord injury: a treatment based on a data glove and an immersive virtual reality environment.

Dimbwadyo-Terrer I, Trincado-Alonso F, de Los Reyes-Guzmán A, Aznar MA, Alcubilla C, Pérez-Nombela S, Del Ama-Espinosa A, Polonio-López B, Gil-Agudo Á.

Disabil Rehabil Assist Technol. 2016 Aug;11(6):462-7. doi: 10.3109/17483107.2015.1027293. Epub 2015 Jul 16.

PMID:
26181226
18.

Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade.

Quetglas JI, Labiano S, Aznar MÁ, Bolaños E, Azpilikueta A, Rodriguez I, Casales E, Sánchez-Paulete AR, Segura V, Smerdou C, Melero I.

Cancer Immunol Res. 2015 May;3(5):449-54. doi: 10.1158/2326-6066.CIR-14-0216. Epub 2015 Feb 17.

19.

Lipid nanoparticles protect from edelfosine toxicity in vivo.

Lasa-Saracíbar B, Aznar MÁ, Lana H, Aizpún I, Gil AG, Blanco-Prieto MJ.

Int J Pharm. 2014 Oct 20;474(1-2):1-5. doi: 10.1016/j.ijpharm.2014.07.053. Epub 2014 Aug 1.

PMID:
25091376
20.
21.

Edelfosine lipid nanoparticles overcome multidrug resistance in K-562 leukemia cells by a caspase-independent mechanism.

Aznar MÁ, Lasa-Saracíbar B, Blanco-Prieto MJ.

Mol Pharm. 2014 Aug 4;11(8):2650-8. doi: 10.1021/mp5000696. Epub 2014 Jun 6.

22.

Involvement of miRNAs in the differentiation of human glioblastoma multiforme stem-like cells.

Aldaz B, Sagardoy A, Nogueira L, Guruceaga E, Grande L, Huse JT, Aznar MA, Díez-Valle R, Tejada-Solís S, Alonso MM, Fernandez-Luna JL, Martinez-Climent JA, Malumbres R.

PLoS One. 2013 Oct 14;8(10):e77098. doi: 10.1371/journal.pone.0077098. eCollection 2013.

23.

Efficacy of edelfosine lipid nanoparticles in breast cancer cells.

Aznar MÁ, Lasa-Saracíbar B, Estella-Hermoso de Mendoza A, Blanco-Prieto MJ.

Int J Pharm. 2013 Oct 1;454(2):720-6. doi: 10.1016/j.ijpharm.2013.04.068. Epub 2013 Apr 30.

24.

Downregulation of FOXP1 is required during germinal center B-cell function.

Sagardoy A, Martinez-Ferrandis JI, Roa S, Bunting KL, Aznar MA, Elemento O, Shaknovich R, Fontán L, Fresquet V, Perez-Roger I, Robles EF, De Smedt L, Sagaert X, Melnick A, Martinez-Climent JA.

Blood. 2013 May 23;121(21):4311-20. doi: 10.1182/blood-2012-10-462846. Epub 2013 Apr 11.

25.

[Effectiveness of a consensus protocol for the prevention of chemotherapy-induced nausea and vomiting].

Pardo MÁ, Lahmar I, Raymundo A, Camacho MD, Martínez M, Talens A, Bujaldón N, Aznar MT.

Farm Hosp. 2012 Nov-Dec;36(6):518-24. doi: 10.7399/FH.2012.36.6.38. Spanish.

26.

Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice.

Vicente-Dueñas C, Fontán L, Gonzalez-Herrero I, Romero-Camarero I, Segura V, Aznar MA, Alonso-Escudero E, Campos-Sanchez E, Ruiz-Roca L, Barajas-Diego M, Sagardoy A, Martinez-Ferrandis JI, Abollo-Jimenez F, Bertolo C, Peñuelas I, Garcia-Criado FJ, García-Cenador MB, Tousseyn T, Agirre X, Prosper F, Garcia-Bragado F, McPhail ED, Lossos IS, Du MQ, Flores T, Hernandez-Rivas JM, Gonzalez M, Salar A, Bellosillo B, Conde E, Siebert R, Sagaert X, Cobaleda C, Sanchez-Garcia I, Martinez-Climent JA.

Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10534-9. doi: 10.1073/pnas.1204127109. Epub 2012 Jun 11.

27.

LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.

Malumbres R, Fresquet V, Roman-Gomez J, Bobadilla M, Robles EF, Altobelli GG, Calasanz MJ, Smeland EB, Aznar MA, Agirre X, Martin-Palanco V, Prosper F, Lossos IS, Martinez-Climent JA.

Haematologica. 2011 Jul;96(7):980-6. doi: 10.3324/haematol.2011.040568. Epub 2011 Apr 1.

Supplemental Content

Loading ...
Support Center